PTPA and neoplasm: These approaches can be broadly categorized into (i) direct pharmacological activation or inhibition of PP2A holoenzymes, (ii) selective targeting of regulatory subunits to restore tumor-suppressive phosphatase activity, and (iii) disruption of endogenous PP2A regulators [110].